[
  {
    "ts": null,
    "headline": "Adimab Reports Strong Partnering Year for 2025",
    "summary": "Adimab, LLC, the global leader in the discovery and engineering of fully human monoclonal and multispecific antibodies, today announced that it entered into partnership agreements with 23 companies in 2025. In addition, Adimab achieved 50 technical and development milestones across numerous collaborations.",
    "url": "https://finnhub.io/api/news?id=0ea5b719e7392abac7aa1fdfe58b8bfdc207fca01ab520e4e7c8d919405bb0a0",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1768247820,
      "headline": "Adimab Reports Strong Partnering Year for 2025",
      "id": 138078029,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Adimab, LLC, the global leader in the discovery and engineering of fully human monoclonal and multispecific antibodies, today announced that it entered into partnership agreements with 23 companies in 2025. In addition, Adimab achieved 50 technical and development milestones across numerous collaborations.",
      "url": "https://finnhub.io/api/news?id=0ea5b719e7392abac7aa1fdfe58b8bfdc207fca01ab520e4e7c8d919405bb0a0"
    }
  },
  {
    "ts": null,
    "headline": "JPM26: Eli Lilly and NVIDIA deepen ties with $1bn AI partnership",
    "summary": "A new co-innovation lab in the San Francisco Bay area will see Lilly and NVIDIA scientists work alongside each other to fuel drug discovery improvements.",
    "url": "https://finnhub.io/api/news?id=23f793c78c415b581d0c860fc6782c56f4311c3b06c6bf327f65bdee953c3270",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1768242358,
      "headline": "JPM26: Eli Lilly and NVIDIA deepen ties with $1bn AI partnership",
      "id": 138077966,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "A new co-innovation lab in the San Francisco Bay area will see Lilly and NVIDIA scientists work alongside each other to fuel drug discovery improvements.",
      "url": "https://finnhub.io/api/news?id=23f793c78c415b581d0c860fc6782c56f4311c3b06c6bf327f65bdee953c3270"
    }
  },
  {
    "ts": null,
    "headline": "TSMC rises on reported US–Taiwan deal, Nvidia & Eli Lilly team up",
    "summary": "Yahoo Finance Senior Reporter Brooke DiPalma tracks Monday's top moving stocks and biggest market stories in this Market Minute. Taiwan Semiconductor Manufacturing Company (TSM) stock is moving higher on a New York Times report that the Trump administration is close to reaching a trade agreement with Taiwan. Nvidia (NVDA) and Eli Lilly (LLY) are partnering on drug discovery, jointly investing $1 billion to create a lab in San Francisco. Stay up to date on the latest market action, minute-by-minute, with Yahoo Finance's Market Minute.",
    "url": "https://finnhub.io/api/news?id=ce6bfe2a5759f4de74f91b898152bd26219752795d0000a584c6afe817abec0b",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1768241694,
      "headline": "TSMC rises on reported US–Taiwan deal, Nvidia & Eli Lilly team up",
      "id": 138077967,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Yahoo Finance Senior Reporter Brooke DiPalma tracks Monday's top moving stocks and biggest market stories in this Market Minute. Taiwan Semiconductor Manufacturing Company (TSM) stock is moving higher on a New York Times report that the Trump administration is close to reaching a trade agreement with Taiwan. Nvidia (NVDA) and Eli Lilly (LLY) are partnering on drug discovery, jointly investing $1 billion to create a lab in San Francisco. Stay up to date on the latest market action, minute-by-minute, with Yahoo Finance's Market Minute.",
      "url": "https://finnhub.io/api/news?id=ce6bfe2a5759f4de74f91b898152bd26219752795d0000a584c6afe817abec0b"
    }
  },
  {
    "ts": null,
    "headline": "Tempus AI's Pharma Momentum Accelerates",
    "summary": "Contract value passes $1.1 billion milestone",
    "url": "https://finnhub.io/api/news?id=ff38bcbc57cd472afc636a8380f0ee88a6ef9e41608fd3600c0ae3a53b8bd375",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1768241298,
      "headline": "Tempus AI's Pharma Momentum Accelerates",
      "id": 138078032,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Contract value passes $1.1 billion milestone",
      "url": "https://finnhub.io/api/news?id=ff38bcbc57cd472afc636a8380f0ee88a6ef9e41608fd3600c0ae3a53b8bd375"
    }
  },
  {
    "ts": null,
    "headline": "Nvidia Partners With Biotech Firms On AI Drug Discovery",
    "summary": "Nvidia announced AI partnerships with two biotech firms to transform the way lifesaving drugs are discovered and manufactured.",
    "url": "https://finnhub.io/api/news?id=7c2ace435a4c627ea6bfc01c102eb0c81e23515e03e8aa450aebb2b41279062b",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1768241156,
      "headline": "Nvidia Partners With Biotech Firms On AI Drug Discovery",
      "id": 138076416,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Nvidia announced AI partnerships with two biotech firms to transform the way lifesaving drugs are discovered and manufactured.",
      "url": "https://finnhub.io/api/news?id=7c2ace435a4c627ea6bfc01c102eb0c81e23515e03e8aa450aebb2b41279062b"
    }
  },
  {
    "ts": null,
    "headline": "BioAge Rockets As It Takes On Eli Lilly's Takeover Play, Ventyx Bio",
    "summary": "BioAge shares catapulted Monday on promising results for the company's cardiovascular diseases treatment, which could eventually rival Eli Lilly.",
    "url": "https://finnhub.io/api/news?id=463efe6e648be96935da61ed43bf3db49a3329f8cd18b40580c7daa7ee9f96b1",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1768241101,
      "headline": "BioAge Rockets As It Takes On Eli Lilly's Takeover Play, Ventyx Bio",
      "id": 138076418,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "BioAge shares catapulted Monday on promising results for the company's cardiovascular diseases treatment, which could eventually rival Eli Lilly.",
      "url": "https://finnhub.io/api/news?id=463efe6e648be96935da61ed43bf3db49a3329f8cd18b40580c7daa7ee9f96b1"
    }
  },
  {
    "ts": null,
    "headline": "Eli Lilly and Nvidia Make $1 Billion AI Bet to Revolutionize Pharma’s Future",
    "summary": "One of the major promises of artificial intelligence (AI) is its role in speeding up drug discovery. AI can process massive amounts of data far faster than humans, identifying potential drug candidates and predicting their effects. This could cut years off the traditional process, which often takes over a decade and costs billions. Eli Lilly ... Eli Lilly and Nvidia Make $1 Billion AI Bet to Revolutionize Pharma’s Future",
    "url": "https://finnhub.io/api/news?id=f26109efab0f7d40aeeb0e39b372565a6c4053aa2e4f3964c1aa9a34a3e26a8d",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1768240097,
      "headline": "Eli Lilly and Nvidia Make $1 Billion AI Bet to Revolutionize Pharma’s Future",
      "id": 138077969,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "One of the major promises of artificial intelligence (AI) is its role in speeding up drug discovery. AI can process massive amounts of data far faster than humans, identifying potential drug candidates and predicting their effects. This could cut years off the traditional process, which often takes over a decade and costs billions. Eli Lilly ... Eli Lilly and Nvidia Make $1 Billion AI Bet to Revolutionize Pharma’s Future",
      "url": "https://finnhub.io/api/news?id=f26109efab0f7d40aeeb0e39b372565a6c4053aa2e4f3964c1aa9a34a3e26a8d"
    }
  },
  {
    "ts": null,
    "headline": "Health Care Roundup: Market Talk",
    "summary": "Find insight on U.S. pharmaceutical companies’ cash positions, the Thai health-care sector and more in the latest Market Talks covering the health care sector.",
    "url": "https://finnhub.io/api/news?id=eda3cf4f73b150dab1efe606ce157882d4fca763716cba74b6697431d4686de4",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1768238940,
      "headline": "Health Care Roundup: Market Talk",
      "id": 138078034,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Find insight on U.S. pharmaceutical companies’ cash positions, the Thai health-care sector and more in the latest Market Talks covering the health care sector.",
      "url": "https://finnhub.io/api/news?id=eda3cf4f73b150dab1efe606ce157882d4fca763716cba74b6697431d4686de4"
    }
  },
  {
    "ts": null,
    "headline": "‘Biotech Super Bowl’ Lands With a Thud. Stocks Slide on Lack of Deal News.",
    "summary": "Monday is the first day of  J.P. Morgan’s  annual healthcare investor conference, which draws thousands of investors, analysts, and executives to San Francisco each year.  There is ample precedent: Last year,  Johnson & Johnson  announced a $14.6 billion deal to acquire Intra-Cellular Therapeutics on the first day of the gathering.  The Wall Street Journal reported last week that Merck was in talks to buy the biotech Revolution Medicines for roughly $30 billion, but as of late morning, no such agreement had been announced.",
    "url": "https://finnhub.io/api/news?id=a8e42fa0176125b6d61a239d1fc7e9d3ac654534ef8fe6ce6ee1a22fdfcc0ed8",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1768235880,
      "headline": "‘Biotech Super Bowl’ Lands With a Thud. Stocks Slide on Lack of Deal News.",
      "id": 138076408,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Monday is the first day of  J.P. Morgan’s  annual healthcare investor conference, which draws thousands of investors, analysts, and executives to San Francisco each year.  There is ample precedent: Last year,  Johnson & Johnson  announced a $14.6 billion deal to acquire Intra-Cellular Therapeutics on the first day of the gathering.  The Wall Street Journal reported last week that Merck was in talks to buy the biotech Revolution Medicines for roughly $30 billion, but as of late morning, no such agreement had been announced.",
      "url": "https://finnhub.io/api/news?id=a8e42fa0176125b6d61a239d1fc7e9d3ac654534ef8fe6ce6ee1a22fdfcc0ed8"
    }
  },
  {
    "ts": null,
    "headline": "Nvidia, Eli Lilly announce $1 billion investment in AI drug discovery lab",
    "summary": "Nvidia and Eli Lilly are set to launch an AI lab in San Francisco.",
    "url": "https://finnhub.io/api/news?id=dfb88457675d7d45a6952ce9f0f47913067984500ac3a5997dee7ff3b20b00e7",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1768235686,
      "headline": "Nvidia, Eli Lilly announce $1 billion investment in AI drug discovery lab",
      "id": 138076328,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Nvidia and Eli Lilly are set to launch an AI lab in San Francisco.",
      "url": "https://finnhub.io/api/news?id=dfb88457675d7d45a6952ce9f0f47913067984500ac3a5997dee7ff3b20b00e7"
    }
  },
  {
    "ts": null,
    "headline": "JPM26: Eli Lilly reportedly eyes €15bn takeover of Abivax",
    "summary": "Abivax’s lead asset is obefazimod, an anti-inflammatory drug that has produced positive Phase III results.",
    "url": "https://finnhub.io/api/news?id=27da8cb109aa3cce69d5422008307a010d9cc74364c345aefdc9909265c9d4ea",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1768234654,
      "headline": "JPM26: Eli Lilly reportedly eyes €15bn takeover of Abivax",
      "id": 138075169,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Abivax’s lead asset is obefazimod, an anti-inflammatory drug that has produced positive Phase III results.",
      "url": "https://finnhub.io/api/news?id=27da8cb109aa3cce69d5422008307a010d9cc74364c345aefdc9909265c9d4ea"
    }
  },
  {
    "ts": null,
    "headline": "Juvena Therapeutics Raises $33.5M Series B Led by Bison Ventures to Advance Regenerative Biologics Pipeline",
    "summary": "REDWOOD CITY, Calif., January 12, 2026--Juvena Therapeutics, a clinical-stage biotechnology company whose AI-enabled regenerative biologics are designed to restore tissue function, today announced its $33.5 million Series B. The round was led by Bison Ventures with participation from Eli Lilly and Company, Jefferson Life Sciences, and existing institutional backers including Mubadala Capital and Manta Ray.",
    "url": "https://finnhub.io/api/news?id=7a4be2e9cf1cd847233f7bc9f55da79d4b5a8a99c6bdf81047fd42378678f1d9",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1768233600,
      "headline": "Juvena Therapeutics Raises $33.5M Series B Led by Bison Ventures to Advance Regenerative Biologics Pipeline",
      "id": 138075170,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "REDWOOD CITY, Calif., January 12, 2026--Juvena Therapeutics, a clinical-stage biotechnology company whose AI-enabled regenerative biologics are designed to restore tissue function, today announced its $33.5 million Series B. The round was led by Bison Ventures with participation from Eli Lilly and Company, Jefferson Life Sciences, and existing institutional backers including Mubadala Capital and Manta Ray.",
      "url": "https://finnhub.io/api/news?id=7a4be2e9cf1cd847233f7bc9f55da79d4b5a8a99c6bdf81047fd42378678f1d9"
    }
  },
  {
    "ts": null,
    "headline": "Nvidia Stock Slips. The Chip Maker Is Launching an AI Lab with Eli Lilly.",
    "summary": "Nvidia  stock was languishing Monday despite news of a partnership with pharmaceutical company  Eli Lilly  The chip company’s investors remain focused progress on sales in China and the health of the wider artificial-intelligence sector.  The stock is down 1.8% over the past month, as a flurry of robotics and autonomous-driving related announcements at the CES trade show, formerly known as the Consumer Electronics Show, failed to provide a boost.  Nvidia said Monday that it was joining with  Eli Lilly  to fund an AI lab with an investment of up to $1 billion over five years to build models for biology and chemistry.",
    "url": "https://finnhub.io/api/news?id=54df798c2d63766e45564573da21ff498421bbc56c99c8f0f074d9850b19abd4",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1768233000,
      "headline": "Nvidia Stock Slips. The Chip Maker Is Launching an AI Lab with Eli Lilly.",
      "id": 138076333,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Nvidia  stock was languishing Monday despite news of a partnership with pharmaceutical company  Eli Lilly  The chip company’s investors remain focused progress on sales in China and the health of the wider artificial-intelligence sector.  The stock is down 1.8% over the past month, as a flurry of robotics and autonomous-driving related announcements at the CES trade show, formerly known as the Consumer Electronics Show, failed to provide a boost.  Nvidia said Monday that it was joining with  Eli Lilly  to fund an AI lab with an investment of up to $1 billion over five years to build models for biology and chemistry.",
      "url": "https://finnhub.io/api/news?id=54df798c2d63766e45564573da21ff498421bbc56c99c8f0f074d9850b19abd4"
    }
  },
  {
    "ts": null,
    "headline": "Nvidia Partners With Eli Lilly on AI Drug Laboratory",
    "summary": "Nvidia plans to invest $1 billion over five years in a new laboratory with Eli Lilly & Co., aiming to speed up the use of artificial intelligence in the pharmaceutical industry. Jessica Nix has more on \"Bloomberg Open Interest.\"",
    "url": "https://finnhub.io/api/news?id=9e0b8714b3e842c5df1dbe47d10f4143798e8a952f435e90816cbfab7a217e96",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1768231663,
      "headline": "Nvidia Partners With Eli Lilly on AI Drug Laboratory",
      "id": 138075083,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Nvidia plans to invest $1 billion over five years in a new laboratory with Eli Lilly & Co., aiming to speed up the use of artificial intelligence in the pharmaceutical industry. Jessica Nix has more on \"Bloomberg Open Interest.\"",
      "url": "https://finnhub.io/api/news?id=9e0b8714b3e842c5df1dbe47d10f4143798e8a952f435e90816cbfab7a217e96"
    }
  },
  {
    "ts": null,
    "headline": "NVIDIA and Lilly Announce Co-Innovation AI Lab to Reinvent Drug Discovery in the Age of AI",
    "summary": "Companies to Jointly Invest up to $1 Billion Over Five Years in Infrastructure and Research NVIDIA and Lilly NVIDIA and Eli Lilly and Company today announced a first-of-its-kind AI co-innovation lab focused on applying AI to tackle some of the most enduring challenges in the pharmaceutical industry. News Summary: NVIDIA and Lilly bring together a world-leading, multidisciplinary team of scientists, AI researchers and engineers to address the hardest problems in drug discovery.The co-innovation l",
    "url": "https://finnhub.io/api/news?id=2ee6fc6f18972234b0d5872b5c80350a159e042fe9f751c7755e66e448ff8a8f",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1768230000,
      "headline": "NVIDIA and Lilly Announce Co-Innovation AI Lab to Reinvent Drug Discovery in the Age of AI",
      "id": 138075090,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Companies to Jointly Invest up to $1 Billion Over Five Years in Infrastructure and Research NVIDIA and Lilly NVIDIA and Eli Lilly and Company today announced a first-of-its-kind AI co-innovation lab focused on applying AI to tackle some of the most enduring challenges in the pharmaceutical industry. News Summary: NVIDIA and Lilly bring together a world-leading, multidisciplinary team of scientists, AI researchers and engineers to address the hardest problems in drug discovery.The co-innovation l",
      "url": "https://finnhub.io/api/news?id=2ee6fc6f18972234b0d5872b5c80350a159e042fe9f751c7755e66e448ff8a8f"
    }
  },
  {
    "ts": null,
    "headline": "NVIDIA BioNeMo Platform Adopted by Life Sciences Leaders to Accelerate AI-Driven Drug Discovery",
    "summary": "NVIDIA BioNeMo NVIDIA today announced a major expansion of NVIDIA BioNeMo, an open development platform that enables lab-in-the-loop workflows to develop breakthroughs in AI-driven biology and drug discovery. News Summary: Lilly and NVIDIA launch AI co-innovation lab to tackle drug discovery challenges.NVIDIA collaborates with Thermo Fisher to build autonomous lab infrastructure for scalable scientific discovery.Chai Discovery, Basecamp Research, Boltz and ecosystem leaders connect NVIDIA BioNeM",
    "url": "https://finnhub.io/api/news?id=22172f7ad7a60ecf47acc0bba7207dc5a6b814acf1a019f4edfc41e3643ce9b0",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1768230000,
      "headline": "NVIDIA BioNeMo Platform Adopted by Life Sciences Leaders to Accelerate AI-Driven Drug Discovery",
      "id": 138075089,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "NVIDIA BioNeMo NVIDIA today announced a major expansion of NVIDIA BioNeMo, an open development platform that enables lab-in-the-loop workflows to develop breakthroughs in AI-driven biology and drug discovery. News Summary: Lilly and NVIDIA launch AI co-innovation lab to tackle drug discovery challenges.NVIDIA collaborates with Thermo Fisher to build autonomous lab infrastructure for scalable scientific discovery.Chai Discovery, Basecamp Research, Boltz and ecosystem leaders connect NVIDIA BioNeM",
      "url": "https://finnhub.io/api/news?id=22172f7ad7a60ecf47acc0bba7207dc5a6b814acf1a019f4edfc41e3643ce9b0"
    }
  },
  {
    "ts": null,
    "headline": "This French Biotech Stock Surged 1,700% in 2025. Eli Lilly Is Taking an Interest.",
    "summary": "Eli Lilly’s  presence in France has spanned more than six decades, but rumors of an acquisition suggest the pharmaceutical giant could be looking to expand its footprint in the country.  French outlet La Lettre reported Monday that biotechnology company  Abivax  had become the subject of takeover interest by Lilly, which was prepared to offer 15 billion euros, or roughly $17.5 billion, to acquire it.  Eli Lilly  has yet to support a formal bid to Abivax’s board as it awaits clarity from French regulators on whether a bid would be subject to France’s foreign investment rules, the outlet reported.",
    "url": "https://finnhub.io/api/news?id=4863a4313bd2a68732a200542749ff832e20657036e679b1d15b211bd6e9aa84",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1768229460,
      "headline": "This French Biotech Stock Surged 1,700% in 2025. Eli Lilly Is Taking an Interest.",
      "id": 138075175,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Eli Lilly’s  presence in France has spanned more than six decades, but rumors of an acquisition suggest the pharmaceutical giant could be looking to expand its footprint in the country.  French outlet La Lettre reported Monday that biotechnology company  Abivax  had become the subject of takeover interest by Lilly, which was prepared to offer 15 billion euros, or roughly $17.5 billion, to acquire it.  Eli Lilly  has yet to support a formal bid to Abivax’s board as it awaits clarity from French regulators on whether a bid would be subject to France’s foreign investment rules, the outlet reported.",
      "url": "https://finnhub.io/api/news?id=4863a4313bd2a68732a200542749ff832e20657036e679b1d15b211bd6e9aa84"
    }
  },
  {
    "ts": null,
    "headline": "Here's Why Eli Lilly (LLY) is a Strong Growth Stock",
    "summary": "The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.",
    "url": "https://finnhub.io/api/news?id=1d0f739a4d5c15705d2c043bf8be08bee088280d2dcd8b365f692d215cd1dd74",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1768229104,
      "headline": "Here's Why Eli Lilly (LLY) is a Strong Growth Stock",
      "id": 138076424,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.",
      "url": "https://finnhub.io/api/news?id=1d0f739a4d5c15705d2c043bf8be08bee088280d2dcd8b365f692d215cd1dd74"
    }
  },
  {
    "ts": null,
    "headline": "Fed Chair Powell Faces US DOJ Criminal Probe, Equity Futures Waver Pre-Bell",
    "summary": "US equity futures were down ahead of Monday's opening bell after the US Department of Justice launch",
    "url": "https://finnhub.io/api/news?id=05959e39eb4c9cbcfeb3c5e93a2757cf5ef1a10aaa556879fc50045d9e7acc73",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1768226721,
      "headline": "Fed Chair Powell Faces US DOJ Criminal Probe, Equity Futures Waver Pre-Bell",
      "id": 138072309,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "US equity futures were down ahead of Monday's opening bell after the US Department of Justice launch",
      "url": "https://finnhub.io/api/news?id=05959e39eb4c9cbcfeb3c5e93a2757cf5ef1a10aaa556879fc50045d9e7acc73"
    }
  },
  {
    "ts": null,
    "headline": "CenterWell Pharmacy to Dispense Obesity Management Medications as Part of New, Employer-Focused Program",
    "summary": "LOUISVILLE, Ky., January 12, 2026--CenterWell Pharmacy to dispense obesity management medications as part of new, employer-focused program.",
    "url": "https://finnhub.io/api/news?id=bc142aeb12de854d53819de49d942cbc593c86ab15b135bd8c8574333c765f82",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1768226400,
      "headline": "CenterWell Pharmacy to Dispense Obesity Management Medications as Part of New, Employer-Focused Program",
      "id": 138072310,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "LOUISVILLE, Ky., January 12, 2026--CenterWell Pharmacy to dispense obesity management medications as part of new, employer-focused program.",
      "url": "https://finnhub.io/api/news?id=bc142aeb12de854d53819de49d942cbc593c86ab15b135bd8c8574333c765f82"
    }
  },
  {
    "ts": null,
    "headline": "RVTY & Eli Lilly Partner to Expand Access to AI Drug Discovery Models",
    "summary": "Revvity teams up with Eli Lilly to bring TuneLab AI models to Signals Xynthetica, aiming to unlock secure, federated drug discovery at scale.",
    "url": "https://finnhub.io/api/news?id=51dac6a3a00be1b2dabef0a8bb2534bfe8cd485deddbec907ce96ce9bc7b5f67",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1768226220,
      "headline": "RVTY & Eli Lilly Partner to Expand Access to AI Drug Discovery Models",
      "id": 138075176,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Revvity teams up with Eli Lilly to bring TuneLab AI models to Signals Xynthetica, aiming to unlock secure, federated drug discovery at scale.",
      "url": "https://finnhub.io/api/news?id=51dac6a3a00be1b2dabef0a8bb2534bfe8cd485deddbec907ce96ce9bc7b5f67"
    }
  },
  {
    "ts": null,
    "headline": "HealthDyne Helps Advance Access to Obesity Treatment by Supporting New Carve-Out Benefit Options",
    "summary": "HealthDyne announced it will participate in alternative access solutions for employers seeking access to FDA-approved obesity management medicine from Eli Lilly and Company (Lilly). HealthDyne will become a dispensing pharmacy for select Lilly medicines collaborating with digital healthcare providers to offer integrated carve-out solutions that combine affordability, clinical oversight and patient engagement.",
    "url": "https://finnhub.io/api/news?id=596a50d3a492d4b6690e7c87ac78372a79f037d55954d684bb638de383a9ff38",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1768225500,
      "headline": "HealthDyne Helps Advance Access to Obesity Treatment by Supporting New Carve-Out Benefit Options",
      "id": 138072311,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "HealthDyne announced it will participate in alternative access solutions for employers seeking access to FDA-approved obesity management medicine from Eli Lilly and Company (Lilly). HealthDyne will become a dispensing pharmacy for select Lilly medicines collaborating with digital healthcare providers to offer integrated carve-out solutions that combine affordability, clinical oversight and patient engagement.",
      "url": "https://finnhub.io/api/news?id=596a50d3a492d4b6690e7c87ac78372a79f037d55954d684bb638de383a9ff38"
    }
  },
  {
    "ts": null,
    "headline": "Wall Street Lunch: Paramount Skydance Takes Fight To Warner's Board To Block Netflix Deal",
    "summary": "Paramount Skydance (PSKY) says it plans to nominate directors to Warner Bros. Discovery (WBD) and has filed suit in Delaware seeking basic information.",
    "url": "https://finnhub.io/api/news?id=97d3718eb8e5e8ca40d8eb640faaadc4e45ac2c057db8fc9a32114dc0dc6ffb9",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1768225029,
      "headline": "Wall Street Lunch: Paramount Skydance Takes Fight To Warner's Board To Block Netflix Deal",
      "id": 138076923,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2254004225/image_2254004225.jpg?io=getty-c-w1536",
      "related": "LLY",
      "source": "SeekingAlpha",
      "summary": "Paramount Skydance (PSKY) says it plans to nominate directors to Warner Bros. Discovery (WBD) and has filed suit in Delaware seeking basic information.",
      "url": "https://finnhub.io/api/news?id=97d3718eb8e5e8ca40d8eb640faaadc4e45ac2c057db8fc9a32114dc0dc6ffb9"
    }
  },
  {
    "ts": null,
    "headline": "Recludix Pharma Announces Equity Financing to Advance Clinical Development of Novel SH2 Domain Inhibitors",
    "summary": "Financing led by institutional investors, with participation from new investor Eli Lilly and CompanyInclusive of this investment, a total of $123 million in equity financing received from institutional and strategic investors to dateSeparately, Recludix announces collaboration with Lilly to utilize Lilly TuneLab™, a pioneering artificial intelligence and machine learning platform, to accelerate the development of Recludix’s discovery pipeline SAN DIEGO, Jan. 12, 2026 (GLOBE NEWSWIRE) -- Recludix",
    "url": "https://finnhub.io/api/news?id=4d8797fa4e4931b07ea478b21d23a1e15bfecd8bb3a6ac5c684be653d8c63bf5",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1768223100,
      "headline": "Recludix Pharma Announces Equity Financing to Advance Clinical Development of Novel SH2 Domain Inhibitors",
      "id": 138071337,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Financing led by institutional investors, with participation from new investor Eli Lilly and CompanyInclusive of this investment, a total of $123 million in equity financing received from institutional and strategic investors to dateSeparately, Recludix announces collaboration with Lilly to utilize Lilly TuneLab™, a pioneering artificial intelligence and machine learning platform, to accelerate the development of Recludix’s discovery pipeline SAN DIEGO, Jan. 12, 2026 (GLOBE NEWSWIRE) -- Recludix",
      "url": "https://finnhub.io/api/news?id=4d8797fa4e4931b07ea478b21d23a1e15bfecd8bb3a6ac5c684be653d8c63bf5"
    }
  },
  {
    "ts": null,
    "headline": "Commonwealth Fusion Systems Names Stephane Bancel to Board of Directors",
    "summary": "Commonwealth Fusion Systems (CFS), the largest and leading private fusion company, today announced that Stephane Bancel, the Chief Executive Officer of Moderna Inc. who led that company's successful development, production, scaling, and global adoption of the COVID-19 vaccine, has joined as an Independent Member of the Board of Directors.",
    "url": "https://finnhub.io/api/news?id=95f822cb870f8a61cb849a98bc47f80cd3606cac228e24b386f1caaeb400869f",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1768222800,
      "headline": "Commonwealth Fusion Systems Names Stephane Bancel to Board of Directors",
      "id": 138071339,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Commonwealth Fusion Systems (CFS), the largest and leading private fusion company, today announced that Stephane Bancel, the Chief Executive Officer of Moderna Inc. who led that company's successful development, production, scaling, and global adoption of the COVID-19 vaccine, has joined as an Independent Member of the Board of Directors.",
      "url": "https://finnhub.io/api/news?id=95f822cb870f8a61cb849a98bc47f80cd3606cac228e24b386f1caaeb400869f"
    }
  },
  {
    "ts": null,
    "headline": "Abivax: Don't Just Buy The Rumor, Buy The Fundamentals",
    "summary": "Abivax (ABVX) stays a Buy as obefazimod UC data fuels multiâbillion potential; 2026 Phase 3/NDA catalysts loom and M&A chatter adds upsideâread more.",
    "url": "https://finnhub.io/api/news?id=169f4fc18dd9191125631cd2e9f1d84bfa3a0e8fcaa5b027584dd3c427842632",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1768221098,
      "headline": "Abivax: Don't Just Buy The Rumor, Buy The Fundamentals",
      "id": 138076132,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1905291067/image_1905291067.jpg?io=getty-c-w1536",
      "related": "LLY",
      "source": "SeekingAlpha",
      "summary": "Abivax (ABVX) stays a Buy as obefazimod UC data fuels multiâbillion potential; 2026 Phase 3/NDA catalysts loom and M&A chatter adds upsideâread more.",
      "url": "https://finnhub.io/api/news?id=169f4fc18dd9191125631cd2e9f1d84bfa3a0e8fcaa5b027584dd3c427842632"
    }
  },
  {
    "ts": null,
    "headline": "Stocks making the biggest moves midday: Citigroup, Abercrombie, Vistra, Duolingo and more",
    "summary": "These are some of the stocks posting the largest moves in midday trading.",
    "url": "https://finnhub.io/api/news?id=e43056ed836c8984329ea32b572720333ff2c0f34fac75e0ad2b9cb968b8e684",
    "source": "CNBC",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1768219873,
      "headline": "Stocks making the biggest moves midday: Citigroup, Abercrombie, Vistra, Duolingo and more",
      "id": 138075805,
      "image": "https://image.cnbcfm.com/api/v1/image/108228553-1763579411007-gettyimages-2230841002-1010_32_ghi-plexi01988.jpeg?v=1768235608&w=1920&h=1080",
      "related": "LLY",
      "source": "CNBC",
      "summary": "These are some of the stocks posting the largest moves in midday trading.",
      "url": "https://finnhub.io/api/news?id=e43056ed836c8984329ea32b572720333ff2c0f34fac75e0ad2b9cb968b8e684"
    }
  },
  {
    "ts": null,
    "headline": "Abivax shares surge after report flags continued Eli Lilly takeover interest",
    "summary": "Investing.com -- Shares in Abivax jumped sharply on Monday after a report said U.S. drugmaker Eli Lilly remains interested in acquiring the French biotech.",
    "url": "https://finnhub.io/api/news?id=9a5af050f9823c58f6273f9cc7660e7ef2749de2aced0293171f4b3f465ac406",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1768216440,
      "headline": "Abivax shares surge after report flags continued Eli Lilly takeover interest",
      "id": 138071340,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Investing.com -- Shares in Abivax jumped sharply on Monday after a report said U.S. drugmaker Eli Lilly remains interested in acquiring the French biotech.",
      "url": "https://finnhub.io/api/news?id=9a5af050f9823c58f6273f9cc7660e7ef2749de2aced0293171f4b3f465ac406"
    }
  },
  {
    "ts": null,
    "headline": "Abivax Surges on Report Eli Lilly is Preparing $17.5 Billion Bid",
    "summary": "Stock in the French company has been rising steadily since late July, and climbed as much as 30% in early trading Monday.",
    "url": "https://finnhub.io/api/news?id=c4bdcf57eb7e453e83321929f6eddddb730777452af7724ba89f998b6a29c3b6",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1768212180,
      "headline": "Abivax Surges on Report Eli Lilly is Preparing $17.5 Billion Bid",
      "id": 138071342,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Stock in the French company has been rising steadily since late July, and climbed as much as 30% in early trading Monday.",
      "url": "https://finnhub.io/api/news?id=c4bdcf57eb7e453e83321929f6eddddb730777452af7724ba89f998b6a29c3b6"
    }
  },
  {
    "ts": null,
    "headline": "? Markets Last Week: Defense Stocks Rose, Beer Beat, Pharma Deal",
    "summary": "How did American oil companies respond to the U.S. action in Venezuela? Why were Constellation investors happy with lower beer sales? Plus, can a big pharmaceutical deal help Eli Lilly compete in a new treatment area? Host Francesca Fontana discusses the biggest stock moves last week and the news that drove them.",
    "url": "https://finnhub.io/api/news?id=c6cde9e5289e7a50040f21af9238a8851e64fc46414cf4bdeb3e7bfbd66d355f",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1768205420,
      "headline": "? Markets Last Week: Defense Stocks Rose, Beer Beat, Pharma Deal",
      "id": 138071343,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "How did American oil companies respond to the U.S. action in Venezuela? Why were Constellation investors happy with lower beer sales? Plus, can a big pharmaceutical deal help Eli Lilly compete in a new treatment area? Host Francesca Fontana discusses the biggest stock moves last week and the news that drove them.",
      "url": "https://finnhub.io/api/news?id=c6cde9e5289e7a50040f21af9238a8851e64fc46414cf4bdeb3e7bfbd66d355f"
    }
  },
  {
    "ts": null,
    "headline": "Powell's criminal investigation, Google's AI shopping push, Boeing deliveries and more in Morning Squawk",
    "summary": "Here are five key things investors need to know to start the trading day.",
    "url": "https://finnhub.io/api/news?id=2a761b0b5d2cbe202995dcf556e712951490c75668bd02db88fdbd60611b3b61",
    "source": "CNBC",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1768203656,
      "headline": "Powell's criminal investigation, Google's AI shopping push, Boeing deliveries and more in Morning Squawk",
      "id": 138075768,
      "image": "https://image.cnbcfm.com/api/v1/image/108177029-1753445937974-gettyimages-2226032540-AFP_67RT8NC.jpeg?v=1768190718&w=1920&h=1080",
      "related": "LLY",
      "source": "CNBC",
      "summary": "Here are five key things investors need to know to start the trading day.",
      "url": "https://finnhub.io/api/news?id=2a761b0b5d2cbe202995dcf556e712951490c75668bd02db88fdbd60611b3b61"
    }
  },
  {
    "ts": null,
    "headline": "Eli Lilly Study Finds Zepbound Dual Treatment Improves Arthritis, Helps Patients Lose Weight",
    "summary": "On Thursday, Eli Lilly and Co. (NYSE:LLY) revealed topline results from the novel TOGETHER-PsA open-label Phase 3b trial evaluating the concomitant use of Taltz (ixekizumab) and Zepbound (tirzepatide) compared to Taltz alone for active psoriatic arthritis (PsA) and obesity or overweight with at least one weight-related condition. Psoriatic arthritis is linked to psoriasis (a condition that affects skin and nails). It causes joint pain, stiffness, and a skin rash. At 36 weeks, treatment with conc",
    "url": "https://finnhub.io/api/news?id=175c9fe0964bd08de26e6e887367aed5d3e10773dbc8b95aa13197d063f7525e",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1768181494,
      "headline": "Eli Lilly Study Finds Zepbound Dual Treatment Improves Arthritis, Helps Patients Lose Weight",
      "id": 138068850,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "On Thursday, Eli Lilly and Co. (NYSE:LLY) revealed topline results from the novel TOGETHER-PsA open-label Phase 3b trial evaluating the concomitant use of Taltz (ixekizumab) and Zepbound (tirzepatide) compared to Taltz alone for active psoriatic arthritis (PsA) and obesity or overweight with at least one weight-related condition. Psoriatic arthritis is linked to psoriasis (a condition that affects skin and nails). It causes joint pain, stiffness, and a skin rash. At 36 weeks, treatment with conc",
      "url": "https://finnhub.io/api/news?id=175c9fe0964bd08de26e6e887367aed5d3e10773dbc8b95aa13197d063f7525e"
    }
  }
]